ENZALUTAMIDE
Total Payments
$4.8M
Transactions
928
Doctors
74
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2,000 | 1 | 1 |
| 2018 | $4.7M | 913 | 65 |
| 2017 | $122,409 | 14 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.0M | 689 | 84.1% |
| Consulting Fee | $730,906 | 119 | 15.3% |
| Travel and Lodging | $25,927 | 61 | 0.5% |
| Food and Beverage | $3,915 | 53 | 0.1% |
| Education | $191.00 | 6 | 0.0% |
Payments by Type
Research
$4.0M
689 transactions
General
$760,938
239 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance | Astellas Pharma Global Development | $921,027 | 0 |
| A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY ADT VERSUS PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER MHSPC | Astellas Pharma Global Development | $806,050 | 6 |
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance ENACT | Astellas Pharma Global Development | $572,915 | 0 |
| Feasibility study of adjuvant enzalutamide for the treatment of early stage AR triple negative breast cancer | Astellas Pharma Global Development | $397,324 | 0 |
| Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in CRPC | Astellas Pharma Global Development | $170,831 | 0 |
| EnzaRadiCate | Astellas Pharma Global Development | $167,173 | 0 |
| A Phase II Randomized Prospective Trial of DocetaxelPrednisone Versus DocetaxelPrednisone and Enzalutamide in Castration-Resistant Prostate Cancer CRPC Patients Progressing on Enzalutamide | Astellas Pharma Global Development | $144,786 | 0 |
| A Phase III Trial of Concurrent Chemohormonal Therapy Using Enzalutamide MDV-3100 and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer | Astellas Pharma Global Development | $110,022 | 0 |
| Evaluate the effect of Enzalutamide in Bladder Cancer | Astellas Pharma Global Development | $77,138 | 0 |
| Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy SRT Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy | Astellas Pharma Global Development | $65,775 | 0 |
| Phase II trial of enzalutamide for castrate-resistant prostate cancer CRPC with correlative assessment of androgen receptor AR signaling and whole-exome and transcriptome sequencing | Astellas Pharma Global Development | $56,573 | 0 |
| A PHASE II TRIAL OF ANDROGEN DEPRIVATION, DOCETAXEL AND ENZALUTAMIDE IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER | Astellas Pharma Global Development | $50,816 | 0 |
| Randomized Phase II screening trial of enzalutamideMDV-3100 and LHRH analogue vs combined androgen deprivation LHRH analogue bicalutamide in metastatic hormone sensitive prostate cancer | Astellas Pharma Global Development | $47,970 | 0 |
| A phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer before or after progression on docetaxel | Astellas Pharma Global Development | $42,489 | 0 |
| A Phase II Trial of Enzalutamide in Patients with Androgen Receptor Positive AR Ovarian, Primary Peritoneal and Fallopian Tube Cancer and One, Two or Three Prior Therapies | Astellas Pharma Global Development | $41,534 | 0 |
| Comparing CRPC Patients Outcomes between an Advanced Prostate Cancer Center and the Primary Urology Office | Astellas Pharma Global Development | $32,960 | 0 |
| Enzalutamide plus Everolimus in Men with Metastatic Castrate-Resistant Prostate Cancer and Previous Treatment with Docetaxel A Phase I Study with a Maximum Tolerated Dose Expansion Cohort | Astellas Pharma Global Development | $32,220 | 0 |
| Test Enzalutamide in pre-clinical patient-derived xenograft PDX models of bone metastatic prostate cancer. | Astellas Pharma Global Development | $31,560 | 0 |
| The Role of enzalutamide in Prostate Cancer Radiation Therapy | Astellas Pharma Global Development | $26,824 | 0 |
| EXTEND Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Naive Prostate Cancer | Astellas Pharma Global Development | $25,660 | 0 |
Top Doctors Receiving Payments for ENZALUTAMIDE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $3.9M | 431 |
| , M.D | Diagnostic Radiology | Boston, MA | $90,610 | 7 |
| , MD | Nuclear Medicine | New York, NY | $74,730 | 10 |
| , MD | Nuclear Medicine | Boston, MA | $63,640 | 7 |
| , M.D | Body Imaging | Boston, MA | $62,400 | 6 |
| , MD | Nuclear Medicine | Boston, MA | $62,080 | 7 |
| , MD | Body Imaging | Boston, MA | $55,400 | 6 |
| , M.D | Diagnostic Radiology | Boston, MA | $48,170 | 6 |
| , MD | Diagnostic Radiology | Boston, MA | $43,370 | 6 |
| , M.D | Diagnostic Radiology | West Roxbury, MA | $41,840 | 6 |
| , M.D | Diagnostic Radiology | Burlington, MA | $35,910 | 7 |
| , MD | Nuclear Medicine | Boston, MA | $31,940 | 5 |
| , M.D | Diagnostic Radiology | Boston, MA | $24,510 | 6 |
| , M.D | Urology | Sacramento, CA | $23,271 | 10 |
| , DR | Urology | Myrtle Beach, SC | $19,523 | 60 |
| , M.D | Urology | Nashville, TN | $14,784 | 43 |
| , MB,CHB | Internal Medicine | Ann Arbor, MI | $12,356 | 67 |
| , M.D | Hematology & Oncology | Chicago, IL | $9,995 | 14 |
| , M.D | Urology | Denver, CO | $9,840 | 14 |
| , MD | Urology | Poughkeepsie, NY | $8,238 | 8 |
| , MD | Internal Medicine | Boston, MA | $7,840 | 2 |
| , MD | Urology | West Bloomfield, MI | $7,595 | 8 |
| , M.D | Urology | Baltimore, MD | $7,454 | 7 |
| , M.D | Hematology & Oncology | New Haven, CT | $6,889 | 9 |
| , MD | Hematology & Oncology | Crystal Lake, IL | $6,628 | 9 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $4.7M
- Astellas Pharma US Inc $80,230
- Astellas Pharma Europe BV $6,500
- CIPLA USA INC. $2,000
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 74
- Transactions 928
About ENZALUTAMIDE
ENZALUTAMIDE is a drug associated with $4.8M in payments to 74 healthcare providers, recorded across 928 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2020. In 2020, $2,000 was paid across 1 transactions to 1 doctors.
The most common payment nature for ENZALUTAMIDE is "Unspecified" ($4.0M, 84.1% of total).
ENZALUTAMIDE is associated with 20 research studies, including "A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance" ($921,027).